ALSO IN THIS MONTH'S ISSUE
Democratic House Passes Rx Price Controls Amid Pandemic
During this COVID-19 crisis, government should be collaborating closely with industry to promote innovation that will save lives, improve health and bring back prosperity that can come with safely reopening the economy. Yet, it is astonishing that House Democrats have chosen the opposite path.
Leading And Managing Change During A Time Of Transition And Cultural Transformation
While strategic leadership during times of transition and transformation can be especially challenging, consistently prioritizing organizational goals and strategies is paramount to success.
Helping Managers Navigate Through The “New Normal”
We determined that the skillset needed to lead change during this period of turbulence could be described as 3Cs: Calming – Creating – Connecting, and that each of the 3Cs would comprise a virtual training session.
OTC Drug Monograph Reform In The CARES Act
In March, Congress included in the CARES Act long-awaited reforms to the FDA regulation of OTC drugs. The changes are intended to address challenges with the old system, allowing for more nimble OTC oversight and potentially ushering in a new era of OTC safety and innovation.
The Viral Startup
ViralClear, formed in March 2020 to obtain a drug whose potential use against COVID-19 already has substantial support in evidence. The company is employing considerable industry expertise to move it into clinical development.
BEYOND THE PRINTED PAGE
Lawrence Blatt: Biopharma Entrepreneur And Professional Musician
Lawrence Blatt, Ph.D., cofounder and CEO of Aligos Therapeutics, his latest biopharma entrepreneurial venture, provides insight into the music industry, as he happens to also be a professional musician.
A Biopharma CEO Not Focused On Stock Price
BioNTech’s founder and CEO, Ugur Sahin, M.D., Ph.D., subject of an upcoming feature in Life Science Leader, provides perspective on the company’s IPO and stock price as a metric.
Disappointments In Alzheimer’s Therapeutic Development — A Conversation With John LaMattina
A question from a reader for Life Science Leader's popular monthly Ask The Board column, prompts a Q&A discussion with John LaMattina, Ph.D., on the retreat from neuroscience R&D.
Measuring CAPA Effectiveness: Critical Tips in Getting the Right CAPA and Showing It Works
July 15 - 15, 2020
1pm-2:30pm EST, Online Training Duration: 90-Minutes
Price: $299 - Includes Bonus Handouts!
Regulatory Affairs in China – The New Drug Regulatory Framework
July 16 - 16, 2020
1pm-2:30pm EDT, Online Training Price: $299 - Includes Bonus Handouts!
European Diabetes Conference
July 20 - 21, 2020
4th Global Congress on Medical & Clinical Case Reports
July 22 - 23, 2020
Global Summit On Cancer Research & Therapy
July 22 - 23, 2020